DR info

臨床試験数 : 11 / 薬物数 : 17 - (DrugBank : 5) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 15

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Afamelanotide
   CLINUVEL EUROPE LTD
      2021   Phase 2   EUCTR2021-003642-20-DE   Germany;
   Clinuvel Europe Limited
      2021   Phase 2   NCT05159752   Germany;
Afamelanotide (16 mg implant)
   CLINUVEL EUROPE LIMITED
      2022   Phase 2   EUCTR2021-001419-10-ES   Belgium;Spain;
      -   Phase 2   EUCTR2021-001419-10-BE   Belgium;Spain;
Biospecimen Collection
   National Cancer Institute (NCI)
      2021   Phase 1   NCT04500548   Canada;United States;
Ipilimumab
   National Cancer Institute (NCI)
      2021   Phase 1   NCT04500548   Canada;United States;
Isotretinoin
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      1991   -   NCT00025012   United States;
Liposomal T4N5 lotion
   Applied Genetics
      1996   Phase 3   NCT00002811   Germany;United Kingdom;United States;
Nivolumab
   National Cancer Institute (NCI)
      2021   Phase 1   NCT04500548   Canada;United States;
Trabectedine
   Pharma Mar, S.A. Sociedad Unipersonal
      2011   Phase 2   EUCTR2010-022968-13-BE   Belgium;Spain;
YONDELIS 0,25 mg polvo para concentrado para solución para perfusión
   PharmaMar S.A. Sociedad Unipersonal
      2011   Phase 2   EUCTR2010-022968-13-ES   Belgium;Spain;
YONDELIS 1 mg polvo para concentrado para solución para perfusión
   PharmaMar S.A. Sociedad Unipersonal
      2011   Phase 2   EUCTR2010-022968-13-ES   Belgium;Spain;
Yondelis 0.25 mg powder for concentrate for solution for infusion.
   Pharma Mar, S.A. Sociedad Unipersonal
      2011   Phase 2   EUCTR2010-022968-13-BE   Belgium;Spain;
Yondelis 1 mg powder for concentrate for solution for infusion.
   Pharma Mar, S.A. Sociedad Unipersonal
      2011   Phase 2   EUCTR2010-022968-13-BE   Belgium;Spain;